Guidance, NICE advice and quality standards in development

Showing 351 to 360 of 372

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]	Technology appraisal guidance	TBC
Urinary Tract Infection (recurrent): antimicrobial prescribing	NICE guideline	13 November 2024
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]	Technology appraisal guidance	20 November 2024
Vamorolone for treating Duchenne muscular dystrophy [ID4024]	Technology appraisal guidance	TBC
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]	Technology appraisal guidance	TBC
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]	Technology appraisal guidance	TBC
Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565	Technology appraisal guidance	TBC
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040]	Technology appraisal guidance	TBC
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291]	Technology appraisal guidance	TBC
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]	Technology appraisal guidance	TBC